The guidelines’ lead author ... that evidence scrutinizing the long-term relationship between obesity treatment and eating disorders was thin — calling it “a gap in the literature.” ...

Updated European guidelines for metabolic dysfunction–associated steatotic liver disease stressed a higher risk in people ...

Obesity—the bad word everyone throws around, but few want to truly understand. The American Academy of Pediatricians thought ...

Researchers have unveiled a novel approach to tackle obesity by targeting fat absorption in the small intestine. The ...

As a pediatric obesity medicine specialist, I have witnessed first-hand the benefits of GLP-1 receptor agonists in the ...

Discover the growing demand for specialty training in obesity treatment as new options emerge. Learn about the current state and benefits of certification ...

The cutting-edge nanoparticle system, engineered to deliver therapeutic molecules directly to the digestive tract, has shown significant potential to prevent diet-induced obesity.

John M. Burke, MD, examines how new obesity treatments, such as GLP-1 agonists, might influence future cancer rates.

Thousands of people with severe obesity are being denied access to effective treatment because the NHS rollout of the ...

She sees many people assuming that the GLP-1 agonists and related types of drugs will be the right treatment for everyone coping with obesity, or that GLP-1 agonists will be the wrong treatment ...

Doctors have said access to the drug is a "postcode lottery" as Sky News analysis reveals just 800 people have been ...

A new study published in the journal of Diabetes Care found that pediatric obesity with metabolic dysfunction-associated ...